二甲双胍改善腹主动脉瘤患者来源的主动脉平滑肌细胞功能
研究取腹主动脉瘤患者(n=21)和对照(n=17)的主动脉活检,体外培养平滑肌细胞并给予或不给予二甲双胍处理。结果发现二甲双胍增加腹主动脉瘤患者平滑肌细胞收缩性和代谢活性,降低增殖、迁移和炎症,非糖尿病与糖尿病腹主动脉瘤患者间效应相似。
要点
- 二甲双胍增加腹主动脉瘤患者平滑肌细胞在离子霉素刺激下的收缩性(p=0.001)。
- 二甲双胍增加平滑肌细胞代谢活性(p<0.001),降低增殖(p<0.001)和迁移。
- 二甲双胍降低腹主动脉瘤患者平滑肌细胞炎症标志物MCP-1、IL-6基因表达和NF-κB p65蛋白表达。
核心结论
- 本研究发现二甲双胍在体外增加主动脉平滑肌细胞收缩性和代谢活性,并降低增殖、迁移和炎症。
研究设计与样本
- 取腹主动脉瘤患者(n=21)和对照(n=17)手术时的主动脉活检,从组织块培养非病理性主动脉对照、非糖尿病腹主动脉瘤患者和糖尿病腹主动脉瘤患者的平滑肌细胞,给予或不给予二甲双胍处理。
主要发现
- 二甲双胍处理前,非糖尿病与糖尿病腹主动脉瘤患者平滑肌细胞间KLF4和GYS1的mRNA表达存在差异(p<0.041)。
- 二甲双胍对非糖尿病与糖尿病腹主动脉瘤患者各种平滑肌细胞功能的作用相似。
- 刺激后,二甲双胍增加腹主动脉瘤患者平滑肌细胞的收缩性(p=0.001)。
- 二甲双胍处理后腹主动脉瘤患者平滑肌细胞收缩表型标志物smoothelin的mRNA表达增加(p=0.006)。
- 对照和腹主动脉瘤患者平滑肌细胞给予二甲双胍后代谢活性增加(p<0.001)、增殖(p<0.001)和迁移降低。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Type 2 diabetes mellitus (T2DM) is a cardiovascular risk factor. Paradoxically, a decreased risk of abdominal aortic aneurysm (AAA) presence and growth rate is described among patients with T2DM, associated with metformin use. This study aimed to investigate the effect of metformin on AAA patient-derived aortic smooth muscle cell (SMC) function. METHODS: Aortic biopsies were obtained from patients with AAA (n = 21) and controls (n = 17) during surgery. The SMCs of non-pathological aortic controls, non-diabetic patients with AAA, and diabetic patients with AAA were cultured from explants and treated with or without metformin. The SMC contractility was measured upon ionomycin stimulation, as well as metabolic activity, proliferation, and migration. mRNA and protein expression of markers for contraction, metabolic activity, proliferation, and inflammation were measured. RESULTS: mRNA expression of KLF4 and GYS1, genes involved in metabolic activity, differed between SMCs from non-diabetic and diabetic patients with AAA before metformin stimulation (p < .041). However, the effect of metformin on the various SMC functions was similar between non-diabetic and diabetic patients with AAA. Upon stimulation, metformin increased the contractility of AAA patient SMCs (p = .001). mRNA expression of smoothelin, a marker for the contractile phenotype, increased in SMCs of patients with AAA after treatment with metformin (p = .006). An increase in metabolic activity (p < .001) and a decrease in proliferation (p < .001) and migration were found in the SMCs of controls and patients with AAA with metformin. Increased mRNA expression of PPARγ, a nuclear receptor involved in mitochondrial biogenesis (p < .009), and a decrease in gene expression of Ki-67, a marker for proliferation (p < .005), were observed. Gene expression of inflammation markers MCP-1 and IL-6, and protein expression of NF-κB p65 decreased after treatment with metformin in patients with AAA. CONCLUSION: This study found that metformin increases contractility and metabolic activity, and reduces proliferation, migration, and inflammation in aortic SMCs in vitro.
引用
- van Merrienboer TAR, Rombouts KB, Bogunovic N, et al. Metformin Improves the Function of Abdominal Aortic Aneurysm Patient-Derived Aortic Smooth Muscle Cells. Eur J Vasc Endovasc Surg. 2024. PMID: 39321955. doi:10.1016/j.ejvs.2024.09.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。